Custom Search

News

Tuesday 01 April 2003

Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy.

By: Paschal BR.

Leuk Lymphoma 2003 Apr;44(4):731-3

Denileukin diftitox (ONTAK) is indicated for the treatment of patients with cutaneous T cell lymphoma. Clinical experience with this drug in other lymphomas is limited. This case report concern a patient with stage IV follicular lymphoma who, relapsing after autologous transplant and having failed multiply systemic therapies, including retuximab and CHOP, achieved a prolonged remission with denileukin diftitox.

Use of this site is subject to the following terms of use